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1. Introduction
Although malignant melanoma (MM) is mainly a sporadic disease, about 3 to 15% of the
cases may show familial aggregation [1, 2]. The diagnosis of melanoma in different members
of the same families does indeed suggest there is a genetically-based hereditary predisposi‐
tion in a significant percentage of the cases. However, this predisposition has proven to be
genetically heterogeneous. Only two high-penetrance genes had been described so far:
CDKN2A and CDK4 [1]. Yet mutations in these genes are found in only 30–40% of melano‐
ma kindreds, indicating the existence of additional genes involved in melanoma predisposi‐
tion [1]. Also, common low-penetrance alleles of the human pigmentation MC1R gene have
been implicated in melanoma predisposition as well [3-13]. More recently, several other pig‐
mentation genes, such as ASIP, TYR, TYRP1, SLC45A2 and OCA2 have also emerged as be‐
ing potentially important in both normal human pigmentation variation and in melanoma
susceptibility [14-17].
Other putative low-penetrance genes involved in melanoma predisposition are DNA repair
genes belonging to the base excision repair (BER) and the nucleotide excision repair (NER)
mechanisms. BER and NER pathways eliminate a wide variety of DNA damage, including
ultraviolet (UV) photoproducts. Therefore, the ability of each individual to repair DNA
damage following different causes might explain at least in part the variability in melanoma
susceptibility. Although several studies have investigated the association between polymor‐
phisms in NER genes and risk of melanoma, most of the study sizes were relatively small,
and the results were not consistent [18-24]. On the other hand, genetic polymorphisms have
been identified in several BER genes and studies suggest that some of these polymorphisms
may be associated with cancer risk [25-29].
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Further candidate low-penetrance genes allegedly linked to melanoma predisposition are
members of the glutathione S-transferase (GST) gene family. GSTs are multifunctional en‐
zymes involved in the detoxification of a wide range of reactive oxygen species (ROS)
which, together with inflammatory response to UV exposure, contribute to skin carcinogen‐
esis by oxidative stress mechanisms [30-32]. Since UV radiation can also indirectly induce
oxidative stress via ROS, several GST genes have been considered as possible low-pene‐
trance melanoma predisposition genes. Among the GST genes, GSTM1, GSTT1 and GSTP1
commonly harbor functional polymorphisms in the general population [33]. The frequencies
of variants in the GSTM1 and GSTT1 genes have been studied in relation to susceptibility to
melanoma; however, conflicting results have been reported [34-39].
In recent years, several genome-wide association studies (GWAS) have identified novel ge‐
nomic loci associated with pigmentation and skin cancer [40-44]. GWAS are the ideal strat‐
egy to identify common, low-penetrance susceptibility loci without prior hypothesis bias
due to gene role knowledge. Some of the associations detected were already known, such as
MC1R with pigmentation and skin cancer, ASIP, TYR, OCA2, etc. However, several novel
chromosomal regions and genes have been revealed using large cohorts of samples, such as
IRF4, PARP1, CASP8, CCND1 and others.
What follows is a summary of the results obtained in our laboratory after the screening of
genes belonging to three different genetic pathways: pigmentation, DNA repair and oxida‐
tive stress. For the past few years, our group has been studying melanoma candidate genes
in Spain, a southern European population, displaying a considerably darker skin than most
of the other well-studied Caucasian populations, including Australian, North American and
Northern Europe populations.
2. Research methods
2.1. Study subjects and data collection
A case-control collection of 946 non-related MM cases from several Spanish Hospitals and
353 volunteer cancer-free controls were recruited from 1 September 2004 to January 2011.
All participants were Caucasians of Spanish origin. A standardized questionnaire was used
to collect information on pigmentation characteristics (eye, hair and skin color, number of
nevi, presence of solar lentigines, sun exposure habits and presence of childhood sunburns),
Fitzpatrick’s classification of skin type (extracted from the medical record of cases only), tu‐
mor localization, Breslow index (depth index), and personal or family history of cancer. All
study subjects gave informed consent and the study was approved by the Ethics Committee
of Gregorio Marañón General University hospital and Clínico University Hospital.
Genomic DNA from cases and controls was isolated from peripheral blood lymphocytes
and diluted to a final solution of 50ng/ml. MagNA Pure LC Instrument DNA extracción was
used according to the manufacturer’s protocol (Roche Applied Science, Mannheim, Germa‐
ny); the DNAzol procedure (Invitrogen, Eugene, OR, USA) or traditional saline method was
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used. DNA concentration was quantified in samples prior to genotyping by using Quant-iT
PicoGreen dsDNA Reagent (Invitrogen, Eugene, OR, USA).
2.2. SNP genotyping
2.2.1. MC1R sequencing
MC1R variants were detected by automated gene sequencing. The MC1R coding region was
amplified by PCR using two overlapping pairs of primers previously described [9]. PCR
products were 671 and 610 bp in length, respectively, and they overlapped by 104 bp. PCR
amplification was performed according to Matichard and cols [9]. Sequence analysis was
performed on the ABI Prism system (Life Technology, Foster city, CA) using the BigDye
Terminator Cycle Sequencing kit and the ABI 3700 automated DNA sequencer according to
the manufacturer’s instructions. The sequence results were analyzed using Polyphred,
Phred Phrap and Consed software [45-47] or SeqScape in order to detect all possible
changes. All detected changes were confirmed manually.
2.2.2. Gene and SNP selection
The rest of the genes in the study were analyzed by genotyping selected SNPs. Public data‐
bases were used to collect information about single nucleotide polymorphisms (SNPs):
NCBI (http://www.ncbi.nlm.nih.gov), Ensembl (http://www.ensembl.org/index.html) and
HapMap (http://www.hapmap.org). SNPs selected were located in exons, in putative pro‐
moter regions or had been reported to be associated with cancer in previous studies. All
SNPs had a minor allele frequency (MAF) greater than or equal to 5%. As a quality control
measure we included two sample duplicates and a non-template sample per 96-well plate.
For some high-throughput platforms three DNA duplicates (two intra-assays and one inter-
assay) were added. For all the studies performed genotypes were scored by two different
personnel in the laboratory and no discrepancies were observed.
2.2.3. Taqman and kaspar assays
The PCR primers and probes were designed by Life Technology (Foster City, CA) using
their Custom Taqman SNP genotyping assays or KASPAR SNP Genotyping System KBio‐
sciences (Hoddesdon, Herts UK). The primer and allele-specific probe sequences for Taq‐
man as well as those used for Kaspar assays are detailed elsewhere [6, 7, 14, 16, 17, 27].
PCR conditions used were according to the manufacturer’s protocol (Life technology, Foster
City, CA). After PCR, the genotype of each sample was automatically determined by meas‐
uring allele-specific final fluorescence in the ABI Prism 7900HT Detection System, using the
SDS 2.1 software for allele discrimination (Life technology, Foster City, CA).
2.2.4. Sequenom
Genotyping  assays  were  designed  according  to  the  Sequenom  MassARRAY  Assay  De‐
sign  software  (version  3.0.0;  Sequenom  Inc.,  San  Diego,  CA,  USA).  Assay  primers  are
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detailed elsewhere [15, 27].  One duplicate sample, one father–mother–child trio and two
negative  controls  were  included across  the  plates  to  assess  the  accuracy  of  genotyping.
SNPs  were  genotyped  using  iPLEXTM  chemistry  on  a  MALDI-TOF  Mass  Spectrometer
(Sequenom  Inc,  San  Diego,  CA,  USA).  PCR  reactions  were  carried  out  according  to
their own instructions (Sequenom Inc.).
2.2.5. Illumina
A total of 384 SNPs were genotyped using the GoldenGate Genotyping Assay system ac‐
cording to the manufacturer’s protocol (Illumina, San Diego, CA, USA) [16]. Genotyping
was carried out using 350 ng of DNA per reaction. In addition, cases and control samples
were always included in the same run. Genotypes were called using the proprietary soft‐
ware supplied by Illumina (BeadStudio, version 3.1.3.).
2.2.6. Taqman quantitative real-time PCR
The GSTM1 and GSTT1 copy number polymorphisms were determined using the TaqMan
Quantitative real-time PCR. Assay designs were Hs02575461_cn (GSTM1) and
Hs000100004_cn (GSTT1) and were used according to Life Technology instructions. After
PCR, the genotype of each sample was automatically determined by measuring allele-specif‐
ic final fluorescence in the ABI Prism 7900HT Detection System, using the SDS 2.3 software
for allele discrimination (Life Technology, Foster City, Ca, USA). Analysis of PCR products
was done using the COPY CALLER Software v1.0 (Life Technology, Foster City, USA) that
allowed the classification of unambiguous homozygous (zero copies), heterozygous (one
copy) and homozygous (two copies) GSTM1 or GSTT1 carrier individuals.
2.3. Statistical analysis
Associations between MC1R variants and melanoma risk were initially assessed individual‐
ly using Fisher’s exact test. Associations with melanoma were assessed using logistic regres‐
sion. Estimating odds ratios (ORs), their associated 95% confidence intervals (CIs) and P-
values were obtained using SPSS v19. Multivariate logistic regression was also applied,
including age, sex, hair color, skin color, solar lentigines and childhood sunburn as covari‐
ates. Associations between the number of variants carried and various individual and tumor
characteristics were assessed via logistic regression.
To study the effect of combined protective and risk genotypes, we reduced the sample set to
528 samples successfully genotyped for all the associated SNPs. We used a 2x2 contingency
table and a t-student test between SLC45A2 (rs35414) and both SILV (rs2069398) and NOS1
(rs2682826), as well as with all three genes together. In addition, we studied the results be‐
tween the risk alleles, TYR (rs17793678), ADAMTS20 (rs1510521), GSTP1 (rs1695) and OCA2/
HERC2 (rs12913832). Finally, we analyzed possible interactions between MC1R (0, 1 or 2
variants) and all previous risk and protective alleles
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3. Results
3.1. MC1R
Of the 946 individuals studied, 559 (59.15%) carried at least one MC1R variant, including 388
(65.43%) of 593 cases and 171 (48.4%) of the 353 controls. A total of 36 MC1R variants were
identified.
Among these, 25 variants were non-synonymous changes, 20 of which had been described
previously [5] and 5 were identified for the first time: S41F, M128T, P268R, A285V and
N281S. Six variants of the receptor have been traditionally associated with red hair color
(RHC): D84E, R142H, R151C, R160W, I155T and D294H.
Similarly, another three variants have not been associated with RHC phenotype and have
been designated as NRHC (V60L, V92M and R163Q). These amino acid changes have been
studied in different populations because their frequency is greater than 1%.
The other variants detected in the MC1R gene have frequencies lower than 1% in control
samples and included C35Y, F45L, a trinucleotide deletion that results in a new amino acid
in position 54 (c.161delTGG, V54E), S83P, G89R, V92L, T95M, a nonsense change (Y152X),
two nucleotide insertions (c.537insC, p.ins179C; and c.537insT, p.ins179T), R213W, R272M,
K278E, and T308M, plus all novel ones described before. These rare variants have been des‐
ignated as “ns_rare SNPs” in Figure 1. The synonymous variants included the most com‐
mon change, T314T (A>G), and the rare changes I63I, Q233Q, I264I, F300F as well as I180I
and S316S, the last two described for the first time. These synonymous variants are called
“s_rare” with or without T314T in Figure 1. The estimated frequency of common MC1R var‐
iants and some combinations such as all synonymous changes with and without the com‐
mon T314T and all non-synonymous rare variants, as well as the corresponding estimated
OR for MM and associated P-values are shown in Figure 1.
Among the 36 changes detected, five were individually associated with melanoma risk:
V60L, R151C, I155T, R160W and D294H (P< 0.05). The highest OR was estimated for I155T
(OR 3.65, 95% CI: 1.40–9.52; P=0.006). The estimated OR associated with carrying one non-
synonymous variant was 1.58 (95% CI: 1.19–2.097; P =0.0013); however, the OR for carrying
two non-synonymous variants was 4.38 (95% CI: 2.72–7.05; P =1.33x 10-9). The MM associat‐
ed OR among those Spanish patients carrying one RHC variant was 2.36 (95% CI: 1.71–3.26;
P =1.86 x10-7). However if we consider individuals homozygous or compound heterozygous
for two RHC variants, the OR increased to 12.76 (95% CI: 3.06–53.29; P =1.9 x10-5).
We considered blue ⁄green eye color, blond ⁄red hair color, solar lentigines and childhood
sunburns as confounders in a multivariate model. MC1R variant analysis retained statistical‐
ly significant results when adjusted for all potential confounders (OR: 1.77, 95% CI: 1.37–
2.27; P =9.57x 10-6). Hair color, solar lentigines and childhood sunburns were independently
associated with MM (OR: 2.11, 95% CI: 1.22–3.66, P=0.008; OR: 2.28 95% CI: 1.61–3.23,
P=3.54x10-6; OR: 4.77, 95% CI: 3.37–6.77, P =9.57x 10-6, respectively).
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Figure 1. a) Summary of all MC1R variants associated with MM. Odds Ratios (OR), 95% confidence interval (95% CI)
and P-values. b) Minor Allele Frequencies (MAF) of MC1R genetic variants. ns: non-synonymous variants :V60L, V92M,
S83P, D84E,V122M, R142H, R151C, I155T R160W, R163Q and D294H; s_rare SNPs: synonymous variants with MAFs in
controls lower than 1%: I63I, I180I, Q233Q, I264I, F300F and S316S; s_rare +T314T: same variants as before plus the
addition of T314T; ns_rare SNPs: non-synonymous variants with less than 1% frequency in controls: C35Y;S41F, F45L,
54delTGG, G89R, V92L,T95M, M128T, Y152X, 179insTor C, R213W, P268R, T272M, K278E, N281S, A285V and T308M.
Grey squares represent control data whereas black bars represent MM cases. Dark circles denote statistically signifi‐
cant values.
3.2. Other genes from pathways associated to melanoma
Several studies have been performed in order to evaluate other pigmentation-related genes
and their relationship to MM susceptibility. The first results generated by Fernandez and
cols. [4] analyzed the oculocutaneous albinism (OCA) genes: TYR (MIM#606933), OCA2
(MIM#611409), TYRP1 (MIM#115501) and SLC45A2 (MIM#606202); the melanocyte protein
SILV (MIM#155550) and MC1R inverse agonist ASP (MIM#600201).
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Allele frequencies for each SNP and the P-value for their comparisons between case and con‐
trol subjects are detailed in Figure 2. After discarding two of the selected SNPs, one in the OCA2
gene due to its monomorphic nature in our sample collection, and one in the SLC45A2 gene due
to its departure from HWE, we observed evidence of differences in allele frequency for one
SNP in the SLC45A2 gene, corresponding to F374L (NCBI dbSNP rs16891982). The estimated
OR per minor allele copy was 0.41 (95% CI, 0.24–0.70; P =0.001) with the minor allele being more
frequent in controls than cases (16% vs. 7%; adjusted P=0.001).
Figure 2. Odds ratios (OR), 95% confidence interval (95% CI), P-values and Minor Allele Frequency (MAF) for the best
seven genetic variants in genes belonging to pigmentation, DNA repair and oxidative stress pathways. Grey bars rep‐
resent control data while black bars represent MM cases. Dark circles denote statistically significant values. Exact P-
values are indicated in number.
In a second study we genotyped 384 SNPs from 65 genes belonging mainly to the pigmenta‐
tion pathway [16]. Ten SNPs located on six individual chromosomes (one in each of
ADAMTS20, TYR and SILV/CDK2; two in each of KIT and MYO7A; and three in SLC45A2)
constituted the top ten MM phase I associated SNPs in our sample after establishing a re‐
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strictive P-value threshold of 0.01. A phase II validation study was conducted to analyze the
most significant SNP of each of the 6 candidate genes. One SNP, rs35414 in the SLC45A2
gene, had an unadjusted P=0.002 in this phase II and overall OR of 0.75 (95% CI 0.67–0.84,
P=0.0001) (Figure 2). None of the other five SNPs tested in phase II reached statistical signifi‐
cance at this stage. However, three of them, located in TYR, SILV/CDK2 and ADAMTS20
had an overall P<0.05 when phase I and II were considered together.
After  analysis  of  genes  in  the  pigmentation pathway,  we conducted two studies  where
16  genes  belonging  to  both  base  excision  repair  (BER)  and  nucleotide  excision  repair
(NER) pathways,  as well  as 14 genes involved in oxidative stress,  including GSTT1  and
GSTM1, were screened for copy number variation [17, 27]. Two statistically significant re‐
sults suggested a putative role of oxidative stress processes in the genetic predisposition
to melanoma.
First of all, a novel variant in the NOS1 oxidative stress gene (rs2682826) was detected
(P=0.01). A second association pointed to GSTP1 polymorphism rs1695, encoding the amino
acid change I105V, and individually associated with MM (OR: 1.32, 95%CI: 1.06–1.63,
P=0.01) found associated with melanoma for the first time. The best seven SNPs associated
with MM in our population are shown in Figure 2. We could not detect any association be‐
tween GSTM1 or GSTT1 deletions and MM risk.
3.3. Phenotypic characteristics
If we take into account MC1R and the associated phenotypic characteristics we detect the
estimated ORs for melanoma associated with various phenotypic characteristics based on
univariate analyses. MM risk was associated with the presence of blond or RHC (OR: 4.86,
95% CI: 2.35–10.03, P=2x10-5), solar lentigines (OR: 1.71, 95% CI: 1.04–2.81, P =0.032) and
childhood sunburn (OR: 10.41, 95%CI: 5.81–18.65, P=3x10-13). No association with melanoma
risk was observed for eye color, skin color or number of nevi.
The number of MC1R variants was statistically significantly associated with blond or RHC
(OR: 1.80, 95% CI: 1.26–2.58, P=0.001), fair skin (OR: 1.42, 95% CI: 1.06–1.89, P=0.018) and
with the presence of childhood sunburn (OR: 1.71, 95% CI: 1.28–2.27, P= 2x10-4). The corre‐
sponding ORs for the number of functional MC1R variants were 2.32 (95% CI: 1.42–3.78,
P=0.001) for blond or RHC, 1.58 (95% CI: 1.09–2.3, P= 0.014) for fair skin and 2.35 (95% CI:
1.6–3.45, P=5 x10-5) for the presence of childhood sunburn.
We assessed whether SLC45A2 polymorphisms were associated with various phenotypic
characteristics. The F374L variant allele was associated with dark eye color, dark hair color,
darker skin and absence of both solar lentigines and childhood sunburns. Finally, we tested
for associations between SLC45A2 SNPs and phototype, tumor location, and tumor depth
among cases only (Table 5). The minor (G) allele of the F374L variant was found to be associ‐
ated with phototypes III/IV (per allele OR, 3.25; 95% CI, 1.05–10.03; P=0.04). Additionally,
SLC45A2 SNPs rs35414 and rs35415 were also associated with dark skin color (P=0.028 and
P=0.0485) and only rs35414 with dark hair color (P=0.0183).
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Evidence of association with phenotypic characteristics for two KIT SNPs, rs759083 and
rs13135792, were also present. Both SNPs appeared to be associated with both light hair col‐
or (P=0.0021 and P=0.0072) and childhood sunburns (P=0.0112 and P=0.0167).
Two different SNPs in MYO7A were associated with dark hair color (rs948970, P=0.04), and
childhood sunburn (rs3758708, P=0.0474). One SNP in the TYR gene (rs17793678) was associ‐
ated with light eye color (P=0.0239). Likewise, the ADAMTS20 gene was associated with
light eye color (P=0.0339), blond or red hair color (P=0.0353) and with number of nevi
(rs1510521; P=0.0338). Finally, SILV/CDK2 SNP rs2069398 was associated with absence of
childhood sunburns (P=0.0353).
3.4. Gene-gene interactions
We explored the combined effects of the individually associated SNPs located in the six rele‐
vant genes studied: SLC45A2, SILV, NOS1 (protective associated genes) and TYR,
ADAMTS20 and GSTP1 (risk associated genes). Although in our series it does not show in‐
dividual association with MM, we added rs12913832 from the OCA2/HERC2 gene due to its
strong association with eye color [6, 48] and the fact that it has been demonstrated to have
epistatic effects with the MC1R gene [49].
3.4.1. Interaction between protective alleles
Two SNPs, rs16891982 and rs35414, located in the SLC45A2 gene were associated with MM.
Both of them could have been used to perform the interaction analyses; however, rs35414
was chosen due to its higher MAF. SNPs rs2069398, located in the SILV/CDK2 gene region,
and rs2682826 in NOS1 were also included in the analyses. Interaction results are shown in
Figure 3.
We observed some degree of epistatic protective interaction between rs35414 (SLC45A2
gene) and rs2069398 (SILV/CDK2 gene region) when considering rare allele carriers at both
loci. A significant decrease in MM associated OR was observed when two (heterozygotes for
both SLC45A2 and SILV) or three (heterozygous for SLC45A2 and minor homozygotes for
SILV) rare alleles were present at both loci (OR: 0.54, 95% CI: 0.39–0.75, P=0.0003). Similarly,
when three (minor homozygotes for SLC45A2 and heterozygous for SILV) or four (minor ho‐
mozygous for both SLC45A2 and SILV) rare alleles were carried, a greater decrease in MM
risk was observed (OR: 0.31, 95% CI: 0.18–0.55, P=0.0001). Results including joint genotypes
for rs35414 and rs2069398 SNPs, individual status (heterozygous or minor homozygous),
ORs with their corresponding 95% CIs and P-values are shown in Figure 3a.
In addition, we observed some degree of epistatic protective interaction between rs35414
(SLC45A2) and rs2682826 (NOS1) when considering heterozygote alleles at both loci (OR
0.23, 95% CI 0.16–0.55, P=0.0001). However, a trend toward protective effect was detected
when both homozygous rare alleles were compared (OR: 0.50, 95% CI 0.18–1.20; P=0.1). This
lack of statistically significant results is most probably due to the reduced number of sam‐
ples in this category (21 MM cases vs. 17 controls). Results are shown in Figure 3b.
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The interaction analyses between NOS1 rs2682826 SNP and SILV rs20693989 SNP revealed a
trend toward significance when both rare alleles are considered (OR: 0.19, 95% CI: 0.03–1.07,
P=0.055). Results are shown in Figure 3c.
Figure 3. Interaction between protective allele variants and their effect on MM susceptibility. a) SLC45A2 and SILV, b)
SLC45A2 and NOS1, c) NOS1 and SILV and d) SLC45A2, NOS1 and SILV all together. OR: odds ratios per minor allele;
95% CI: 95% confidence intervals; REF: reference value; HET: heterozygotes; and HMIN: minor homozygotes. For the
genes labeled in vertical, we joined heterozygotes and minor homozygotes. Dark circles denote statistically significant
results.
Finally, when the effect of the interaction between the three loci protectively associated with
MM, rs35414 (SLC45A2), rs2682826 (NOS1) and rs2069398 (SILV) were analyzed, statistically
significant results were observed. Individuals heterozygous for the three genes were more
common in controls than in MM cases (OR: 0.09, 95% CI: 0.022–0.316, P=0.0001), showing a
cumulative protective effect. The comparison with rare homozygous alleles in all three loci
was statistically not relevant due to the small number of samples found (Figure 3d).
3.4.2. Interaction between risk alleles
In order to show the distinct combinations of MM risk alleles we performed two different
analyses. The first comparison studied the effect in MM susceptibility by taking together
four genotypes: rs17793678 (TYR), rs1510521 (ADAMTS20]; rs1695 (GSTP1), and rs12913832
(OCA2/HERC2). Results are shown in Figure 4a-d.
Some degree of epistatic risk interaction was seen between rs17793678 (TYR) and rs1510521
(ADAMTS20) when considering either heterozygous or rare alleles at both loci. We observed
an increased risk effect when two or three rare alleles were present at both loci (rs17793678
heterozygotes and rs1510521 heterozygous, and minor homozygous carriers; OR: 1.41, 95%
CI: 1.12–1.78, P=0.004). When three or four rare alleles (rs17793678 minor homozygotes and
rs1510521 heterozygotes, and minor homozygous carriers) were analyzed together, we ob‐
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tained an OR of 1.54 (95% CI 0.96–2.48) with a trend toward significance (P=0.088). Results
are shown in Figure 4a.
Figure 4. Interactions between risk allele variants and their effect on MM susceptibility. a) TYR and ADAMTS20, b)
GSTP1 and TYR, c) GSTP1 and OCA2/HERC2 and d) TYR and OCA2/HERC2. OR: odds ratios per minor allele; 95% CI:
95% confidence intervals; REF: reference value; HET: heterozygotes; H MIN: minor allele homozygotes; and MIN: only
minor homozygotes for TYR and GSTP1 respectively. For genes labeled in vertical we joined heterozygous and minor
homozygous status. Dark circles denote statistically significant results.
A similar effect was observed when we compared rs1695 (GSTP1) with both rs1510521
(ADAMTS20) and rs12913832 (OCA2/HERC2) polymorphisms. We detected some degree of
epistatic risk interaction when considering homozygous rare alleles at both loci. Results for
rs1695 and rs1510521 showed an OR of 2.53 (95% CI 1.005–6.49, P=0.04, data shown in Fig‐
ure 4b), while the interaction between rs1695 and rs12913832 had an OR of 2.81 (95% CI
1.11–7.27, P=0.018, see Figure 4c).
An additional comparison with rs17793678 (TYR) and rs12913832 (HERC2/OCA2) showed
increasing epistasis as the number of risk alleles augmented, showing a trend toward signifi‐
cance only when homozygous minor alleles were considered at both loci, OR=2.95 (95% CI
0.84–11.326] (p=0.077). See Figure 4d. All other complex comparisons did not add further in‐
formation.
For the second type of analyses we included the MC1R locus together with the previous four
polymorphisms. As MC1R had already been associated with MM, it seemed biologically
plausible that genetic interactions would be detected between risk variants within MC1R
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and other associated genes. Indeed, increased risks appeared when heterozygotes or rare al‐
leles at MC1R were combined with heterozygotes plus rare homozygous at GSTP1 (OR: 5.3,
95% CI: 2.80–417.42; P =1x10-4, see Figure 5a), at TYR (OR: 6.42; 95% CI 2.32–18.64; P=0.0001,
see Figure 5b), and at OCA2/HERC2 (OR: 7.163; 95% CI 2.659–20.05; P=0.0001, see Figure 5c).
Figure 5. Interactions between risk allele variants on MC1R together with other risk associated genes alone or in mul‐
tiple combinations, and their effect on MM susceptibility. a) MC1R and GSTP1, b) MC1R and TYR, c) MC1R and OCA2/
HERC2 and d) MC1R, TYR and OCA2/HERC2, e) MC1R, GSTP1, TYR and OCA2/HERC2. OR: odds ratios per minor allele;
95% CI: 95% confidence intervals; REF: reference value; HET: heterozygotes; H MIN: minor allele homozygotes. For the
genes labeled in vertical we joined heterozygotes and minor homozygotes. Dark circles denote statistically significant
results.
The last group of comparisons was done taking into consideration three and four genes at
the same time. Firstly, we showed that combining MC1R genotypes with both TYR and
GSTP1 resulted in the highest MM associated risk (OR: 11.56, 95% CI 2.25–79.54, P=0.0001;
data shown in Figure 5d). Secondly, we performed a final analysis taking into account only
rare homozygotes of the four risk alleles and compared them, for MM association, with wild
type genotype individuals. We obtained an OR of 4.008 (95% CI 1.25–13.2) with a P-value of
0.016 (see Figure 5e). There is not enough power to consider any other comparison with stat‐
istical significance.
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Figure 6. Interactions between risk variants on MC1R compared with protective alleles in a) SLC45A2, b) SLC45A2,
NOS1 and SILV, and their effect on MM susceptibility. OR: odds ratios per minor allele; 95% CI: 95% confidence inter‐
vals; WT: wild type alleles; MC1R 0: normal sequence in the MC1R gene; MC1R 1: carriers of 1 non-synonymous variant
in MC1R; MC1R 2/+: carriers of two or more non-synonymous variants in the MC1R gene. For the genes labeled in
vertical we have joined heterozygotes and minor homozygotes. Red circles represent carriers of risk alleles in MC1R
whereas green circles correspond to carriers of risk alleles in MC1R and protective alleles either in SLC45A2 alone or in
combination.
3.4.3. Complex interactions
The role of SLC45A2 and the other protective genes (NOS1 and SILV) in melanoma predis‐
position was further analyzed in relation to MC1R, the main low-penetrance gene associated
to melanoma. Since all these genes have been studied by our group, we analyzed the inter‐
action effects between both MC1R and SLC45A2 loci (see Figure 6a) and between MC1R and
all the protective alleles (see Figure 6b).
A great reduction of risk was detected when the rare protective alleles at SLC45A2 were car‐
ried in individuals with two MC1R variants (OR: 2.20, 95% CI 1.14–4.23, P=0.02), in compari‐
son to individuals carrying only two MC1R variants (OR: 4.64; 95% CI 1.85–11.58, P=0.001).
Individuals having only one MC1R mutation plus the rare protective SLC45A2 allele also
Low-Penetrance Variants and Susceptibility to Sporadic Malignant Melanoma
http://dx.doi.org/10.5772/53097
71
showed a reduction in MM risk, although this decline does not seem to reach significant val‐
ues (data shown in Figure 6a). These results confirmed the protective role of the rs35414 var‐
iant in SLC45A2 regarding MM risk. Similar effects are observed when we included in the
calculations the protective SNPs located in NOS1 and SILV, however less statistically signifi‐
cant results were obtained due to the small number of samples in each class.
4. Discussion
Since MC1R genetic variability is strongly associated with the RHC phenotype [12], a large
number of studies have investigated the involvement of this gene in MM susceptibility.
MC1R is highly polymorphic, with more than 100 variants described in Caucasian popula‐
tions [13]. Despite of its high variability, the synonymous changes are greatly reduced, with
only three described in the literature: T314T (A>G), F300F (C>T) and C273C (C>T) [50, 51].
Results obtained from our laboratory confirmed the association between five MC1R poly‐
morphic variants and MM risk in the Spanish population. We found 36 MC1R variants, this
number being quite similar to the number found in other Mediterranean population studies
(16 in France, 26–29 in Italy and 18 in Greece) [9, 11]. The most frequent Spanish variant is
V60L with a frequency of 12.03%. This value is close to that reported in other populations
(15.7% among Northern Italians, 12.4% among fair-skinned Australians and 15.0% among
Northern Europeans) [52]. The RHC phenotype-associated variants (R151C, R160W and
D294H) were present at frequencies of 0,71, 0.71 and 1.42%, respectively, in our population,
compared to 9.9, 8.7 and 3.6%, respectively, reported in Northern European populations
[52]. There were very few red-haired individuals among the control sample, and only 36
(6%) of MM cases had red hair. This finding is consistent with other results from Mediterra‐
nean populations and is at odds with red hair frequencies found in Northern European pop‐
ulations [12]. Red-haired subjects with no MC1R variants are not uncommon and have been
seen in a Northern European population as well [53].
RHC variants have been consistently associated with MM in Northern European popula‐
tions [3, 10, 12] and also in the Northern French population [9]. In Spain, we detected statis‐
tically significant individual associations for R151C, R160W and D294H. These three
variants have been detected in the Northern French and Central Italian populations [9, 54].
We did not observe any MM risk associated with the rare RHC variant D84E (OR: 1.63, 95%
CI: 0.02–128, P= 0.99), as detected in Northern Europeans [32, 55, 56], probably due to its low
prevalence in Spain (0.28% in controls). The I155T variant has not been associated with MM
in other populations to date, but this may also be due to its low frequency. However, our
results clearly suggest that this rare variant increases risk of MM, at least in the Spanish pop‐
ulation (OR: 3.51, 95% CI: 1.35–9.12, P= 0.006). While the associations of RHC with MM were
expected, the case of V60L (an NRHC variant) was more intriguing, since its involvement in
MM pathology has been generally unclear in Caucasian populations. However, V60L could
play a role in MM susceptibility only in darker skinned populations since it has been found
associated with MM in other Mediterranean populations such as France and Greece [9, 11].
The fact that NRHC variants could be important in MM risk is also supported by our find‐
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ing that risk increased with the number of non-synonymous changes carried, regardless of
whether they were RHC or NRHC. The presence of two non-synonymous changes implies
that both copies of the MC1R protein are compromised. In addition, the presence of two
NRHC increases by more than five times the risk of only one non-synonymous variant
(P=1.9x10-5). All these results taken together strongly support the role of the MC1R gene as
highly linked to the susceptibility of developing MM in Mediterranean countries such as
Spain [3, 5, 10, 52].
In  recent  years,  SLC45A2  has  joined  the  group  of  genes  (including  MC1R,  OCA2,  and
ASP) identified as being related to pigmentation, and it is now considered integral to pig‐
mentation variation. Mutations in the SLC45A2 or MATP gene (MIM #606202), which enc‐
odes the membrane-associated transporter, have recently been associated with the OCA4
albinism subtype [57]. The non-synonymous variant F374L (rs16891982) has been reported
to have a strong association with dark hair, skin and eye color in Europeans [58]. These
phenotypic correlations were replicated in our analysis on the Spanish population and we
also established for  the first  time its  role  in MM susceptibility [14].  We also found that
other polymorphisms on SLC45A2  other than rs16891982 were also associated with dark
phenotypic characteristics [16], confirming the role of SLC45A2 in pigmentation. A paral‐
lel work by Guedj and cols. [59] also detected association of this variant with melanoma
in  a  French population,  supporting  our  previous  results.  It  has  been proposed that  the
F374 allele causes a reduction of protein function that alters the intracellular trafficking of
melanosomal  proteins,  creating  an  environment  for  decreased  melanin  production  [58].
More than 90% of European genes carry the F374 allele, which is rare or absent in Afri‐
cans. The remaining 10% of people of European descent with the Leucine ancestral allele
(the most common in Africans) appear to have significantly more pigmented skin. There
is a clear evidence of selective sweep of the chromosomal segment around the SLC45A2
gene in the European population, which is consistent with our data [60]. The derived L374
allele  shows  unusually  large  allele  frequency  differences  between  Europeans  and  other
populations, and has reduced haplotype diversity. These patterns are consistent with the
action of recent natural selection on these genes in Europeans.
The NOS1 gene is located on chromosome 12q24.2 and consists of 29 exons, encompassing
more than 160kb of genomic DNA [61] and it is the main NO synthesizing enzyme in the
central nervous system [62, 63]. The rs2682826 SNP is located in the 3’ UTR of exon 29 of the
NOS1 gene and was selected as the tag SNP of one of the most frequent haplotypes. Howev‐
er, rs2682826 seems to be the most likely functional SNP due to its location close to several
miRNAs binding sites in 3’UTR region. Possibly, differences in protein translation might be
elicited depending on the allele present in the mRNA of this gene. No other regulatory ele‐
ment close to this region seems to modulate this gene. We propose this SNP as a novel var‐
iant related to melanoma (P=0.01).
Despite not being able to detect association between MM and the absence of either GSTM1
or GSTT1 copies, minor homozygotes for rs1695 in the GSTP1 gene appeared to be strongly
associated with MM. The latter SNP encodes an amino acid change, I105V, that was descri‐
bed for the first time associated with MM (P =0.01) in our population. This finding is consis‐
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tent with the hypothesis that patients with the GSTP1 V105 variant enzyme have a reduced
ability to detoxify compounds, which results in lower clearance and reduced efficacy. The
GSTP1 V105 variant is associated with a lower thermal stability and altered catalytic activity
to a variety of substrates compared with those for GSTP1 I105 [34].
It seemed biologically plausible that genetic interactions would be detected between sever‐
al of the SNPs identified in our studies, and for that reason we grouped protective alleles
located in the genes SLC45A2,  SILV/CDK2  and NOS1.  On one hand, a great reduction of
risk was detected when rare alleles at these loci  were combined. The strongest protective
combination was between SLC45A2 and SILV/CDK2,  followed by the combination of het‐
erozygote  samples  at  SLC45A2  and NOS1.  Other  protective  effects  were  seen,  although
they did not reach statistical significance due to the low number of samples in the ana‐
lyzed categories.
In order to determine possible genetic interactions between MC1R and the rest of the genes
studied, we compared individuals carrying risk variants in TYR, ADAMTS20 or OCA2/
HERC2 with the MC1R locus. Indeed, increasing risk effects were observed in all compari‐
sons when as more risk alleles accumulated in the same individuals. However, when MC1R
was taken into consideration, the epistatic effect was far stronger, increasing from an OR of
4.38 when combined with GSTP1 up to an OR of 11.56 when MC1R, TYR and GSTP1 hetero‐
zygotes and homozygotes are considered together, and achieving risk effect values similar
to having two MC1R RHC alleles. It is worth mentioning here that some genetic interactions,
for instance between MC1R and OCA2, have already been described among pigmentation
genes [49, 64].
Finally, we tried to see whether protective alleles were going to be able to reduce the risk
induced by the accumulation of risk alleles. Some comparisons were not possible due to the
absence of individuals in some of the categories. Therefore, we present only the results be‐
tween MC1R risk alleles and the more robust protective gene, SLC45A2, alone or in combi‐
nation with NOS1 and SILV. We could indeed observe a great reduction in risk in
individuals carrying two risk alleles in MC1R when simultaneously carrying protective al‐
leles in the other genes. These results are important because the overall risk for an individu‐
al does not rely in only one gene but in the interaction of all his/hers genetic background
and this should be considered in the future.
In summary, we found that five MC1R variants (V60L, R151C, I155T, R160W and D294H)
are individually associated with MM risk in the Spanish population. Carrying two non-syn‐
onymous MC1R variants was associated with even higher risk, more than doubling the risk
of carrying a single variant and having a five time higher risk than when carrying an NRHC
variant. We described for the first time an association with the F374L variant, located on the
SLC45A2 gene, which appears to be a novel protective low-penetrance melanoma suscepti‐
bility gene. We therefore propose an integral study when trying to assert the MM risk of an
individual, because the combination of rare alleles at several loci modulates the final risk/
protective value that predisposes him/her to MM.
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